Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning demand for its shingles vaccine Shingrix ...